ODTX Odyssey Therapeutics (ODTX) Insider Trading, Ownership & Congress Trades
Pharma & Biotech · Biological products, (no diagnostic substances) · CIK 0001882782
Cluster · 7 insidersActivist 13DC-suite buying · 1
House members buying, 1 year
0
STOCK Act, US House only, disclosed up to 45 days after the trade
Funds added, last quarter
60
13F, latest reported quarter
Conversions, 180 days
20
Codes C/M, not in net · no price filed
What the filings say about ODTX
Insiders, 180 days
+$75.3M net bought
7 buyers · 1 seller · 0% of sales under a 10b5-1 plan
Activist stakes (13D), 180 days
4 filings
Largest: 8.0% of the class
Odyssey Therapeutics insider trades (Form 4)
Form 4 buys and sells (codes P and S). Grants, option exercises
and conversions excluded.
Over the last 180 days, Odyssey Therapeutics, Inc. insiders bought a net $75.3M of stock across 12 Form 4 purchases and sales, with 7 insiders buying. Source: SEC Form 4 filings, as of 2026-10-27.
Insider
Filed
Shares
Value
Since filing
Context
- First Form 4 purchase or sale (code P or S) here by this insider on our record.
- The trade is 37.6% of the 3,690,146 shares held after it.
- 6 other insiders bought within 30 days.
- 60 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Insider COULTER JAMES G bought about $25.0M of ODTX on May 11, 2026, the largest insider purchase at the company on our record; 6 other insiders bought within 30 days and 60 funds added in the latest 13F quarter.Context
- First Form 4 purchase or sale (code P or S) here by this insider on our record.
- The trade is 19.7% of the 1,014,851 shares held after it.
- 6 other insiders bought within 30 days.
- 60 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Insider George Simeon bought about $3.6M of ODTX on May 11, 2026; 6 other insiders bought within 30 days and 60 funds added in the latest 13F quarter.Context
- First Form 4 purchase or sale (code P or S) here by this insider on our record.
- The trade is 0.1% of the 1,609,161 shares held after it.
- No other insider sold within 30 days.
- 60 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Insider George Simeon sold about $19.2K of ODTX on May 11, 2026, the largest insider sale at the company on our record; 60 funds added in the latest 13F quarter.Context
- First Form 4 purchase or sale (code P or S) here by this insider on our record.
- The trade is 12.1% of the 1,831,383 shares held after it.
- 6 other insiders bought within 30 days.
- 60 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Insider George Simeon bought about $4.0M of ODTX on May 11, 2026; 6 other insiders bought within 30 days and 60 funds added in the latest 13F quarter.Context
- First Form 4 purchase or sale (code P or S) here by this insider on our record.
- The trade is 0.1% of the 440,981 shares held after it.
- No other insider sold within 30 days.
- 60 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Insider George Simeon sold about $5.0K of ODTX on May 11, 2026, the largest insider sale at the company on our record; 60 funds added in the latest 13F quarter.12 transactions on record
Since filing: total return from the first close after the filing to the latest close, dividend-adjusted. Not a forecast.
Context lines are counts over the filings above and returns from our own price history, never a price level. Not investment advice.
Seven facts, ranked against the sector ·
Rank is not a forecast
Insiders
net +$75.3M over 180 days
+$10.0M of it by a 10%+ holder
more than 99% of Pharma & Biotech
Congress
no House purchase disclosed in the last 12 months
Funds
60 funds bought in last quarter
more than 51% of Pharma & Biotech
Revenue
-100.0% year over year (latest quarter)
the lowest in Pharma & Biotech
Margin
no margin: no revenue reported
Buybacks
no share repurchases reported
Short interest
13.1% of the float short (float per yahoo 2026-10-26) · 5.6 days to cover · settled 2026-09-30
more than 58% of Pharma & Biotech
The situation: each line is one rule over one dataset
SR One Capital Management, LLC disclosed a 5%+ stake (8.0%) in the last six months.
What changed in the last 30 days
Oct 27Insider selling stopped: no sales in 90 days after 3 in the prior 90
Why it matters
The absence is the signal: 3 sales in one 90-day window and none in the next is a change of behaviour, not a filing.
Oct 27Insider buying stopped: no purchases in 90 days after 9 in the prior 90
Why it matters
The absence is the signal: 9 purchases in one 90-day window and none in the next is a change of behaviour, not a filing.
Watch ODTX
A free account keeps a watchlist and can send one email a day when insiders, funds or Congress file on the names in it. No password and no card.
The year, with the filings on it
Total return over 12 months. Each marker is a filing; hover or tap one for the detail.
+19.4%12M
Insider buyInsider sell13D/G stake
Indexed to 100, dividend-adjusted, not a price chart.
When a name files heavily, the largest trades are drawn first.
Who owns ODTX: institutional holders (13F)
13F holdings, latest reported quarter
5,179,262 sh
$96.9M
3,794,883 sh
$71.0M
3,690,146 sh
$69.0M
3,608,443 sh
$67.5M
3,001,198 sh
$56.2M
Congress trades in ODTX
No Congress trades reported
No House member has disclosed a trade in this stock. See what Congress is buying.
Activist and 5% holders (13D/13G)
13D: intends to influence · 13G: passive
SR One Capital Management, LLC
Activist 13D · 2026-05-18
8.0%
SR One Capital Fund I Aggregator, LP
Activist 13D · 2026-05-18
3.9%
SR One Capital Partners I, LP
Activist 13D · 2026-05-18
3.9%
SR One Co-Invest IV, LLC
Activist 13D · 2026-05-18
0.8%
SR One Co-Invest IV-A, LLC
Activist 13D · 2026-05-18
1.2%
ODTX planned insider sales (Form 144)
No planned-sale notices
No insider has filed to sell. Watch this after a run-up.
ODTX mutual fund holders (N-PORT)
Funds ranked by the share of their own portfolio in this stock (N-PORT).
Franklin Biotechnology Discovery Fund
$1.9M position · as of 2026-07-31
0.2%
Select Biotechnology Portfolio
$5.8M position · as of 2026-05-31
0.1%
EQ/T.Rowe Price Health Sciences Portfolio
$104.2K position · as of 2026-06-30
0.1%
Health Sciences Trust
$147.8K position · as of 2026-06-30
0.1%
T. Rowe Price Health Sciences Fund, Inc.
$3.4M position · as of 2026-06-30
0.0%
T. Rowe Price Health Sciences Portfolio
$211.0K position · as of 2026-06-30
0.0%
SEC N-PORT, monthly, about 60 days late · funds ≥ $10M ·
% is the share of the fund's own portfolio
Clinical pipeline
2 registered trials, 1 still running (ClinicalTrials.gov).
A status change is dated here weeks before the press release.
1
Phase 1
0 active
1
Phase 2
1 active
Matched by sponsor name. Trials run under a subsidiary's
own name are not included.
Live price
Daily candles from TradingView, under their licence. No filings marked.
Why this name is on the desk
7 insiders reported buying shares.
The record shows a net $75.3M bought by insiders over 180 days, 60 funds added last quarter. Each figure is a federal filing, dated the day it went public.
ODTX financials
Revenue growth
-100.0%
XBRL, annual
ODTX Stock Sonar score 4/7 axes
Find similar shapesCompareODTX ranks highest on insider conviction (99th percentile) and institutional and government (51st), and lowest on growth (1st), among Pharma & Biotech peers.
4 of 7 axes scored. Each is a percentile against sector peers (all companies when the sector is thin); higher is better. An unscored axis is unmeasured, not low. How it is scored
ODTX filings, in plain words
Are Odyssey Therapeutics insiders buying or selling ODTX?
In the 180 days to 2026-10-27, Odyssey Therapeutics insiders were net buyers, a net $75.3M: $75.3M of purchases and $32.0K of sales reported on Form 4, by 7 buyers and 1 seller.
Read the full summary
In the 180 days to 2026-10-27, Odyssey Therapeutics insiders were net buyers of ODTX, a net $75.3M across purchases and sales reported on Form 4 by 7 buyers and 1 seller. Purchases outweighed sales more than tenfold by value. 7 insiders reported purchases in that window. None of the 3 insider sales was flagged as made under a Rule 10b5-1 plan. 4 activist Schedule 13D filings in the last 180 days declared an intent to influence the company, the largest for 8.0% of the class. Each figure is counted from SEC and House filings as of 2026-10-27, dated the day the filing was made public.
Explore insider trading and ownership data
Every company we track, ranked by each kind of filing
